Compare NRIX & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | ASTH |
|---|---|---|
| Founded | 2009 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2015 |
| Metric | NRIX | ASTH |
|---|---|---|
| Price | $16.40 | $39.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $30.50 | ★ $34.86 |
| AVG Volume (30 Days) | ★ 820.0K | 412.4K |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | $76,987,000.00 | ★ $519,907,752.00 |
| Revenue This Year | N/A | $27.38 |
| Revenue Next Year | $48.05 | $10.78 |
| P/E Ratio | ★ N/A | $78.17 |
| Revenue Growth | ★ 99.31 | 45.90 |
| 52 Week Low | $8.20 | $18.08 |
| 52 Week High | $22.50 | $36.20 |
| Indicator | NRIX | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 84.88 |
| Support Level | $16.02 | $20.62 |
| Resistance Level | $16.71 | N/A |
| Average True Range (ATR) | 0.76 | 1.54 |
| MACD | -0.07 | 0.18 |
| Stochastic Oscillator | 36.24 | 89.62 |
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.